Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A significant number of advanced ovarian cancer patients on poly-ADP-ribose polymerase inhibitors (PARPi) experience platinum-sensitive recurrence. Local treatments are often viable for these recurrences, particularly oligometastatic disease in BRCA-mutated patients.
Area Of Science
- Oncology
- Gynecologic Oncology
- Cancer Therapeutics
Background
- Poly-ADP-ribose polymerase inhibitors (PARPi) are increasingly used as first-line maintenance therapy for advanced ovarian cancer.
- While PARPi has improved survival, data on recurrence patterns during treatment remain limited.
- This study addresses the need for real-world data on recurrence in patients receiving PARPi.
Purpose Of The Study
- To investigate recurrence rates, disease distribution, and treatment strategies in advanced ovarian cancer patients undergoing first-line PARPi maintenance.
- To analyze the characteristics of recurrence, including oligometastatic patterns and platinum-free intervals.
- To evaluate treatment options for platinum-sensitive recurrences in this population.
Main Methods
- A retrospective analysis of a prospectively maintained database.
- Inclusion of patients receiving first-line PARPi maintenance between January 2019 and December 2022.
- Evaluation of recurrence patterns, mutation status (BRCA), and treatment outcomes.
Main Results
- Of 373 patients, 44.8% experienced recurrence after a median follow-up of 38 months.
- BRCA-mutated patients showed a higher likelihood of oligometastatic recurrence (HR 3.014, P=0.002).
- Over one-third of platinum-sensitive recurrent patients were candidates for local treatments; PARPi was continued in 53.7%.
Conclusions
- A substantial proportion of patients on PARPi will experience platinum-sensitive recurrence, often amenable to local therapies.
- BRCA mutation status is a significant predictor of oligometastatic recurrence patterns.
- Further research is needed to optimize follow-up strategies and evaluate the impact of local treatments on post-recurrence survival.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...